Levofloxacin Olikla (Levofloxacin Hemihydrate)

Levofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, enzymes that are essential for DNA replication and transcription. By blocking these enzymes, the drug prevents bacterial cell division, leading to rapid bacterial death and clearance of the infection from ocular tissues.

The dosing regimen for Levofloxacin Olikla is determined by the prescribing eye‑care professional based on the specific infection, severity, and patient factors. Only a qualified clinician should set the frequency and duration of treatment.

Safety data for levofloxacin use in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and under medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Levofloxacin belongs to the fluoroquinolone class, offering broad‑spectrum activity against Gram‑negative and Gram‑positive ocular pathogens. Compared with older agents such as chloramphenicol or macrolides, levofloxacin often provides faster bacterial eradication and a lower risk of resistance, though individual choice depends on susceptibility patterns and clinician preference.

Levofloxacin Olikla should be stored at temperatures below 25 °C, in its original packaging, protected from light and moisture. Do not freeze the solution, and keep the container tightly closed when not in use to maintain sterility.

The solution is applied directly to the affected eye(s) as eye drops. The prescriber will advise the number of drops per dose and the dosing interval, typically ranging from one to several times daily, depending on the infection severity.

Serious risks include severe allergic reactions such as anaphylaxis, worsening of corneal ulcers, and rare systemic hypersensitivity reactions like Stevens‑Johnson syndrome. Patients should be instructed to seek immediate medical attention if they experience signs of a severe reaction.

Individuals with a known hypersensitivity to levofloxacin, other fluoroquinolones, or any component of the formulation should avoid using the product. Caution is also advised for patients with tendon disorders, uncontrolled epilepsy, or those taking interacting ophthalmic medications.